Addendum

Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Addendum to Project A25-128

Report documents

Indication:

Adult patients with advanced HER2-positive gastric or GEJ adenocarcinoma who have received 1 prior trastuzumab-based regimen in first-line therapy

Result of dossier assessment:

Unchanged after addendum: hint of considerable added benefit

19-03-2026 A G-BA decision was published.
G-BA documents on this decision

Project no.: A26-10
Commission: Commission awarded on 10.02.2026 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A26-10_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.